University of CA-San Francisco

The POINT Trial is a randomized double-blind multicenter clinical study led by the University of California, San Francisco, designed to assess the effectiveness of clopidogrel in combination with low-dose aspirin for patients who have experienced a transient ischemic attack (TIA) or minor ischemic stroke. The trial aims to improve patient survival rates free from major ischemic vascular events, including stroke and myocardial infarction, within a 90-day period following treatment initiation.

Since its recruitment launch in May 2010, the POINT Trial has been actively seeking participation from various sites to further investigate the safety and efficacy of the combined medication approach in reducing the risk of serious cardiovascular complications. The study focuses on patients receiving a specific dosage of clopidogrel alongside aspirin, contributing to ongoing advancements in stroke and cardiovascular care.

Generated from the website